Announced details
Treatment of onychomycosis
Kaken Pharmaceutical entered into an agreement with Almirall granting it exclusive rights to develop and commercialize this product in Europe.
Headquartered in Barcelona, Spain, Almirall is a global pharmaceutical company focused on dermatology. Established in 1944, it is listed on the Spanish stock exchange (ALM) and sells its products in more than 100 countries. Sales in 2025 were approximately €1.1145 billion, and it had approximately 2,100 employees.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Jublia® (generic name: efinaconazole; Japanese brand name: Clenafin® 10% nail topical solution) |
| Counterparty | Almirall S.A. (Almirall; Spanish stock exchange code: ALM) |
| Counterparty overview | Headquartered in Barcelona, Spain, Almirall is a global pharmaceutical company focused on dermatology. Established in 1944, it is listed on the Spanish stock exchange (ALM) and sells its products in more than 100 countries. Sales in 2025 were approximately €1.1145 billion, and it had approximately 2,100 employees. |
| Relationship with the Company | Kaken Pharmaceutical entered into an agreement with Almirall granting it exclusive rights to develop and commercialize this product in Europe. |
| Contract Date | July 2021 |
| Launch date | 7 May 2026; launched in Germany (actual) |
| Applicable area | Treatment of onychomycosis |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To help provide patients with a new treatment option.